Related Experiment Video
Updated: Apr 24, 2026
11:20
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
3.8K
Retinal breaks due to intravitreal ocriplasmin.
Ruwan A Silva1, Darius M Moshfeghi1, Theodore Leng1
1Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, CA, USA.
Clinical Ophthalmology (Auckland, N.Z.)
|September 12, 2014
Summary
Ocriplasmin injection for vitreomacular traction can alleviate macular issues but may cause peripheral retinal breaks and detachment. Continued follow-up is crucial even after successful treatment.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacologic Treatments
Background:
- Abnormal vitreomacular interface conditions like vitreomacular traction syndrome and macular holes are common retinal issues.
- Pharmacologic vitreolysis using ocriplasmin offers a potential alternative to traditional surgical interventions.
- Despite potential benefits, pharmacologic vitreolysis carries its own set of risks.
Purpose of the Study:
- To present two case studies of patients treated with intravitreal ocriplasmin for vitreoretinopathies.
- To evaluate the efficacy and potential complications of ocriplasmin in treating vitreomacular traction and macular holes.
- To highlight the importance of ongoing monitoring post-treatment.
Main Methods:
- Two patients with vitreoretinopathy were treated with intravitreal injections of ocriplasmin.
- Case 1 involved vitreomacular traction syndrome.
- Case 2 involved a full-thickness macular hole.
Main Results:
- Ocriplasmin successfully alleviated vitreomacular traction in both cases.
- Peripheral retinal traction was not completely resolved in one patient, leading to retinal breaks.
- This patient subsequently developed a macula-involving retinal detachment.
Conclusions:
- Ocriplasmin can be effective in relieving vitreomacular traction.
- Complications such as retinal breaks and detachment can occur, even with apparent treatment success.
- Close and continued follow-up is essential for patients treated with ocriplasmin to monitor for delayed complications.
